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Abstract
Background: Antigen specificity and IgG subclass could be significant in the natural history of
Chagas' disease. The relationship between the different stages of human Chagas' disease and the
profiles of total IgG and its subclasses were thus analysed here; they were directed against a crude
T. cruzi extract and three recombinant antigens: the T. cruzi kinetoplastid membrane protein-11
(rKMP-11), an internal fragment of the T. cruzi HSP-70 protein192-433, and the entire Trypanosoma
rangeli HSP-70 protein.
Methods: Seventeen Brazilian acute chagasic patients, 50 Colombian chronic chagasic patients (21
indeterminate and 29 cardiopathic patients) and 30 healthy individuals were included. Total IgG and
its subtypes directed against the above-mentioned recombinant antigens were determined by
ELISA tests.
Results: The T. cruzi KMP-11 and T. rangeli HSP-70 recombinant proteins were able to distinguish
both acute from chronic chagasic patients and infected people from healthy individuals. Specific
antibodies to T. cruzi crude antigen in acute patients came from IgG3 and IgG4 subclasses whereas
IgG1 and IgG3 were the prevalent isotypes in indeterminate and chronic chagasic patients. By
contrast, the specific prominent antibodies in all disease stages against T. cruzi KMP-11 and T. rangeli
HSP-70 recombinant antigens were the IgG1 subclass.
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Conclusion: T. cruzi KMP-11 and the T. rangeli HSP-70 recombinant proteins may be explored
together in the immunodiagnosis of Chagas' disease.
Polarising the IgG1 subclass of the IgG response to T. cruzi KMP-11 and T. rangeli HSP-70 
recombinant proteins could have important biological effects, taking into account that this is a 
complement fixing antibody.
Background
Antibodies against several parasitic antigens are copious
during blood-borne parasite infections such as malaria
and Chagas' disease. These humoral immune responses
have been used for diagnosis, following up individuals
throughout the course of a natural infection, vaccination
protocols and evaluating drug therapy efficacy. However,
little is known about these antibodies' specific role or pro-
file according to disease phases. Concerning humoral
responses, it has been described that antibodies against
repeat and/or evolutionary conserved sequences are
highly predominant in parasitic infections such as that
caused by Trypanosoma cruzi, the aetiological agent of Cha-
gas' disease [1-3]. B lymphocytes and antigen specific anti-
bodies seem to be crucial for controlling acute infection
during the course of T. cruzi infection and could deter-
mine the fate of the disease's chronic phase [4]. Indeed, B
lymphocyte-depleted rats and mice have succumbed to
infection with a T. cruzi lethal strain [5,6].
Following human infection with T. cruzi, some individu-
als (mostly children) can develop a symptomatic acute
phase. However, many individuals recover from acute
infection and move on to the indeterminate phase where
there are no symptoms and the parasite's persistence can
only be indirectly detected by serological tests [7]. This
stage of the disease could last several years or even dec-
ades. Some indeterminate chagasic individuals progress to
chronic disease which unfolds in two major clinical set-
tings compromising either cardiac or digestive tissues
[8,9]. Chronic clinical output (cardiopathy or visceral
enlargement) seems to be dependent of the host immune
response and parasite genetics [8,10,11].
It is becoming apparent that an orchestrated humoral and
cellular immune response is needed for controlling T.
cruzi infection. CD4+ and CD8+ T lymphocytes are essen-
tial for eliminating the parasite during the intracellular
stage (amastigotes) [10,11] and antibodies acting alone or
in association with monocytes operate against extracellu-
lar stages (trypomastigotes) [12,13].
With the aim to understand some of the antigen-specific
antibody-mediated responses, the profiles of IgG subclass
antibody responses and their relationship with the differ-
ent stages of human Chagas' disease were thus analysed.
They were directed against a crude T. cruzi antigen and two
parasite recombinant proteins: the kinetoplastid mem-
brane protein-11 (KMP-11), a kinetoplastids conserved
protein [14,15], and an internal fragment of the T. cruzi
heat shock protein-70 protein192-433(HSP-70T), a highly
conserved protein throughout divergent species' evolu-
tion [16,17]. The Trypanosoma rangeli homologous protein
(GenBank accession ABL74477) was also selected to test a
full length HSP-70 protein bearing the carboxy terminal
GMPG motif which is highly immunogenic in rabbits
[18]; it bears 14 copies of the GMPG motif, a higher
number compared to the complete T. cruzi HSP70 protein
(GenBank accession PO5456).
Methods
Parasite antigens
Epimastigote lysate was obtained from IRHO/CO/85/
MTA Colombian T. cruzi I strain in exponential growth in
15% foetal calf serum supplemented-LIT medium
(GIBCO, Invitrogen, USA) at 28°C. Parasites were washed
twice with cold 1× phosphate-buffered saline (PBS), pH
7.0 and suspended at 1.5 × 107 parasites/μL in lysis buffer
(50 mM Tris -HCl pH 7.0, 1% SDS, 2 mM PMSF, 1%
NP40, 5 mM EDTA, 1% β-mercaptoethanol). After sample
boiling at 100°C for 10 min and cooling at 4°C for 3 h,
the sample was spun for 10 min at 13,000 g and the solu-
ble antigen-containing supernatant was stored at -70°C
until use. Protein lysate concentration was determined by
Bradford assay and protein profile analysed by 10%
sodium dodecyl sulphate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and Coomassie blue staining [19].
The T. cruzi KMP-11 recombinant protein (KMP-11r) [20]
and an internal fragment of the T. cruzi HSP-70 protein
(TcHSP-70T, corresponding to amino acids 192-433),
which is conserved and induces functional maturation of
murine and human dendritic cells [21,22], were purified
as previously described [21]. The entire T. rangeli HSP-70
recombinant protein (TrHSP-70) was obtained by cloning
in pQE30 plasmid (Qiagen, Hilden, Germany) the corre-
sponding encoding region of the Colombian T. rangeli Tre
strain which was PCR amplified using 70TreATG (5'-
CTATAGGATCCATGACGTACGAGGGAGCCA-3') and
70TreTGA specific primers (5'CTATAAAGCTTTCAGT-
CAACCTCCTCCACCT-3'). Amplification reactions wereBMC Infectious Diseases 2009, 9:186 http://www.biomedcentral.com/1471-2334/9/186
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performed in a final 50 μL volume containing 250 ng
purified genomic DNA from the parasite, 1× reaction
buffer (10 mM Tris-HCl, pH 9.0, 50 mM KCl, 0.1% Triton
X-100), 2 mM MgCl2, 0.2 mM of each dNTP, 20 pmol of
each primer and 2.6 units of expand high fidelity enzyme
(Roche, Mannheim, Germany).
The reaction took place in a MJ Research PTC-100 DNA
thermocycler running at 35 cycles having the following
amplification profile: 94°C/1 min, 57°C/1 min and
72°C/2:30 min, with final incubation at 72°C for 10 min.
Following ligation and transformation, the obtained
clone was sequenced and the recombinant protein was
over-expressed in Escherichia coli after incubation for 2
hours at 37°C with 0.02 mM IPTG. The soluble protein
was purified on a Ni2+-NTA-agarose affinity column and
eluted with phosphate buffer (50 mM NaHPO4, 300 mM
NaCl) at pH 6.0.
Patient sera
Four groups of donors were enrolled in the study; all of
them participated voluntarily and signed the informed
consent form. Seventeen Brazilian acute chagasic (AC)
patients from Santa Catarina state who were diagnosed by
IgG and IgM immunofluorescence assays were included
[23]. Fifty chronic chagasic patients were also enrolled
who were positive for anti-T. cruzi antibodies in both
immunofluorescence assay and ELISA test [24]. They were
clinically evaluated at Fundación Abood Clínica Shaio
and Instituto Nacional de Salud, Bogotá, Colombia and
classified as being 21 indeterminate patients (IND), corre-
sponding to patients with normal findings on electrocar-
diograms (ECGs) and chest radiographs, and 29 chronic
chagasic cardiopathic patients (CCC) who presented
abnormal findings on ECGs or/and chest radiographs.
Healthy donors (HD) were also included, consisting of 30
people from Colombia who had always lived in non-
endemic areas and had negative serology for T. cruzi. This
study was approved by the Research and Ethics Commit-
tees from the Universidad Javeriana's Science Facultad de
Ciencias, Pontificia Universidad Javeriana and Fundación
Abood Clínica Shaio.
Detecting anti-T cruzi IgG antibodies by ELISA
The ELISA technique was standardised as follows: 96-well
immunoassay plates (Nunc Maxisorp, Apogent, USA)
were sensitised with 0.1 μg parasite lysate/well or 0.5 μg
KMP-11r or 0.1 μg TcHSP-70T and TrHSP-70 recom-
binant proteins for 3 h at 37°C and subsequently over-
night at 4°C. Plates were then washed with 0.05% PBS-
Tween (PBS-T). The wells were incubated for 1 h at 37°C
with blocking solution (5% nonfat dried milk powder in
PBS-T) to avoid unspecific binding. After washing the
wells three times with PBS-T sera at 1:100 dilution for
lysate, KMP-11r and TrHSP-70 recombinant antigens and
1:50 dilution for TcHSP-70T protein, blocking solution
was added to the wells and they were incubated for 2 h at
37°C. Wells were then washed four times with PBS-T and
anti-human IgG (γ-chain specific) alkaline phosphatase
conjugate (Sigma Chemical Co., St. Louis, MO) was
added to blocking solution at 1:15,000 dilution for lysate
and KMP-11r and 1:10,000 for TcHSP-70T and TrHSP-70
proteins. Plates were incubated for 1 h at 37°C. After four
washes with PBS-T, p-nitrophenylphosphate substrate
solution (Sigma Chemical Co., St. Louis, MO) diluted in
diethanolamine buffer (pH 9.8) was added to each well.
The reaction was developed in the dark at room tempera-
ture for 30 min and stopped by adding 0.5 N NaOH. Opti-
cal densities (OD) were determined on a Labsystems
Multiskan plate reader (Vantaa, Finland) at 405 nm wave-
length. Cut-off values were assessed as being mean optical
density value in samples from non-chagasic donors plus 3
standard deviations.
Detecting anti-T cruzi IgG isotypes by ELISA
A 0.1 μg antigen/well concentration for lysate and 0.5 μg/
well for KMP-11r and TrTHSP-70 was used in the ELISA
technique for IgG1, IgG2, IgG3 and IgG4 subclass anti-
body detection (except for KMP-11r IgG3 detection where
0.1 μg/well was used).
Samples were diluted at 1:50 for all assays and anti-
human IgG1, IgG2, IgG3 and IgG4 peroxidase conjugate
(MP Biomedicals, Inc. Ohio, USA) were diluted at 1:500.
Substrate solution was O-phenylendiamine dihydrochlo-
ride (OPD) (Sigma Chemical Co., St. Louis, MO, USA).
Readings were taken at 492 nm wavelength.
Statistical analysis
Differences among groups were assessed by Student's t test
when n ≥ 10 and by Mann-Whitney test when n < 10.
GraphPad Prism 5.0 statistical software was used for both
analyses. They were considered to be statistically signifi-
cant when p < 0.05.
Results
Analysing recombinant proteins and parasite soluble 
proteins
The KMP-11r, TcHSP-70T and TrHSP-70 recombinant
proteins as well as T. cruzi total crude antigen from the
parasite were analysed by SDS-PAGE (Figure 1). As
expected, bands of around 14, 30, and 76 kDa were
observed for KMP-11r, TcHSP-70, and TrHSP-70 recom-
binant antigens, respectively. Purity was >95% as assessed
by Coomassie blue staining.BMC Infectious Diseases 2009, 9:186 http://www.biomedcentral.com/1471-2334/9/186
Page 4 of 11
(page number not for citation purposes)
Detecting anti-T. cruzi IgG antibodies
The results revealed that 76.5% (13 out of 17) of the
patients in the acute phase and 100% of those in the inde-
terminate (No = 21) and cardiopathic (No = 29) chronic
stages recognised T. cruzi lysate proteins. Healthy donors
did not display reactivity against crude parasite antigen.
There was a statistically significant higher mean OD for
anti-T. cruzi IgG levels in sera from patients in both
chronic stages (IND = 1.424 ± 0.14, and CCC = 1.384 ±
0.18) when compared to that from the acute group (0.539
± 0.38), p < 0.0001, Figure 2A).
Figure 2B shows the reactivity of sera from all patient
groups against the KMP-11 recombinant protein. Healthy
donors did not recognise the KMP-11r protein. The per-
centage of chagasic patients presenting specific anti-KMP-
11r protein IgG antibodies having a reactivity value above
cut-off level was 64.7% (11 out of 17) in the acute group
and 100% for both chronic indeterminate and cardio-
pathic groups. The mean OD value of IgG reactivity
against the KMP-11r protein was higher in indeterminate
patients (1.148 ± 0.508) than that found in the acute
group (0.163 ± 0.096, p < 0.0001). Likewise, chronic cha-
gasic cardiopathic patients also had a higher reactivity
level (1.1 ± 0.55) than that observed in the acute group (p
< 0.0001); 35.3% (6 out of 17) acute, 66.6% (14 out of
21) indeterminate and 86.2% (25 out of 29) chronic cha-
gasic cardiopathic patients presented anti-TcHSP-70T
reactivity values higher than the mean value for reactivity
sera. However, it is worth mentioning that healthy donors
recognised the T. cruzi HSP-70T recombinant protein,
showing significant reactivity with absorbance values
ranging from 0.161 to 0.922 (0.438 ± 0.201 mean) (Fig-
ure 2C).
The TrHSP-70 recombinant protein was assayed to test the
recognition of full length HSP-70 by sera from healthy
donors and chagasic patients at different stages of the sick-
ness. Sera from 5 Brazilian acute and 14 Colombian
chronic patients (7 indeterminate and 7 cardiopathic)
were thus also tested for the presence of anti-TrHSP-70
protein antibodies (Figure 2D). The results showed that
most patients in acute (4 out of 5), indeterminate (5 out
of 7) and chronic (6 out 7) phases had specific anti-T. ran-
geli  protein antibodies. Remarkably, sera from healthy
donors did not recognise the T. rangeli HSP-70 protein at
assayed sera dilution.
Their absorbance values were compared to analyse the
relationship of sera reactivity against both T. cruzi and T.
rangeli HSP-70 recombinant antigens. Absorbance values
were thus normalised by subtracting healthy donors'
mean OD values and comparing them on a graph. Figure
3 shows that 11 out of 19 chagasic patients had higher
reactivity against TrHSP-70 than TcHSP-70. On the other
hand, only 7 patients (1 out of 5 acute, 3 out of 7 indeter-
minate and 3 out of 7 cardiopathic groups) exhibited
higher reactivity against TcHSP-70 than TrHSP-70.
Anti-T. cruzi antibody IgG subclass profile
KMP-11 and TrHSP-70 recombinant proteins were meas-
ured in sera from ten patients who exhibited IgG levels
higher than the cut-off value for all antigens used to help
analyse IgG1, IgG2, IgG3 and IgG4 subclass levels against
T. cruzi lysate (Figures 4, 5, 6).
When the IgG antibody subtype was tested against para-
site soluble proteins it was observed that IgG1 and IgG3
were the predominant subclasses in chagasic patients (Fig-
ure 4). Indeed, all sera from chagasic patients (acute, inde-
Purifying recombinant proteins by Ni2+ affinity chromatogra- phy and extracting total soluble proteins from Trypanosoma  cruzi Figure 1
Purifying recombinant proteins by Ni2+ affinity chro-
matography and extracting total soluble proteins 
from Trypanosoma cruzi. Purified T. cruzi KMP-11 recom-
binant protein (KMP-11r), Trypanosoma cruzi truncated HSP-
70 protein (TcHSP-70T), Trypanosoma rangeli HSP-70 recom-
binant protein (TrHSP-70), and crude T. cruzi lysate were 
electrophoresed in 12% SDS-PAGE and stained with 
Coomassie blue. Lane MW corresponds to molecular weight 
markers shown in kDa.BMC Infectious Diseases 2009, 9:186 http://www.biomedcentral.com/1471-2334/9/186
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terminate and cardiopathic) presented IgG3 isotype
antibodies against crude parasite lysate. Interestingly,
IgG1 was detected in both groups of chronic chagasic
patients (indeterminate and cardiopathic) having similar
mean OD values (IND: 0.405 ± 0.1, CCC: 0.345 ± 0.13).
These values were higher than those detected from
patients in the acute phase (p = 0.0002 and p = 0.0016,
respectively). A low IgG4 response was observed in all
chagasic patients (0.08 maximum OD). Most chagasic
patients presented an anti-lysate IgG2 reactivity OD below
the cut-off value.
Figure 5 shows the IgG subclass profile for KMP-11
recombinant antigen. The results indicated that the anti-
bodies generated against KMP-11r by chagasic patients
were of the IgG1 subtype. There were no detectable anti-
KMP-11 specific IgG2, IgG3 or IgG4 subclass antibodies
with the exception of one serum from a patient in acute
phase (subtype IgG2) and another in a chronic cardio-
pathic patient (subtype IgG4); the antibody titre proved
low in both cases.
When the IgG subtype of anti-T. rangeli HSP-70 recom-
binant protein antibodies was studied it was observed that
ELISA for total IgG antibody levels from acute (AC), indeterminate (IND) and cardiac chronic (CCC) chagasic patients and  healthy individuals (HD) against T. cruzi lysate (2A), KMP-11 (2B), truncated T. cruzi HSP-70 (TcHSP-70T) (2C), and T. rangeli  HSP-70 (2D) recombinant proteins Figure 2
ELISA for total IgG antibody levels from acute (AC), indeterminate (IND) and cardiac chronic (CCC) chagasic 
patients and healthy individuals (HD) against T. cruzi lysate (2A), KMP-11 (2B), truncated T. cruzi HSP-70 
(TcHSP-70T) (2C), and T. rangeli HSP-70 (2D) recombinant proteins. Values are given as optical densities at 405 nm. 
The dotted line represents the cut-off values based on the mean of healthy individual values plus 3 standard deviations. Hori-
zontal lines on each group represent mean and standard deviation values, the mean being the larger one. Statistically significant 
differences among chagasic groups are represented by an asterisk.BMC Infectious Diseases 2009, 9:186 http://www.biomedcentral.com/1471-2334/9/186
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HSP-70 specific antibodies were predominantly of the
IgG1 isotype in chronic chagasic patients (both indetermi-
nate and cardiopathic) (Figure 6). IgG3 subclass antibod-
ies were detected in some acute and chronic cardiopathic
patients.
Discussion
Chagas' disease, before becoming confined to Latin-Amer-
ica, had reached the North-American and European conti-
nents through immigration, thus becoming a health
problem in those non-endemic countries [25]. This is an
intriguing parasitic disease due to its chronic natural evo-
lution. However, only 30% of infected individuals during
the indeterminate stage develop later heart or digestive tis-
sue damage, suggesting an early infection control which
may be related to the immune system and also to the par-
asite's strain and the host's genetic factors [8,26]. A spe-
cific antibody response seems to play an important role in
controlling early parasite blood stages as demonstrated by
passive transfer of immune serum [27], monoclonal anti-
bodies [28] or B cells to depleted rats [5]. Dissecting pro-
tective antibody targets against parasite infection has
proved difficult because of the large number of parasite
genes (12,000 genes per haploid genome), from which at
least 1,500 have been cloned [3].
The antibody profile of total IgG and IgG subclasses
against parasite lysate and KMP-11 and HSP-70 recom-
binant proteins was evaluated to understand the course of
antibody response during T. cruzi infection in acute, inde-
terminate and cardiopathic chronic chagasic patients. The
results showed that the number of individuals recognising
crude parasite antigen was significantly higher in patients
in indeterminate and chronic phases than those in the
acute phase. Moreover, indeterminate and chronic patient
sera titre was also higher compared to that of acute
patients. The consistently higher IgG response in chronic
patients occurring with all the antigens used was also
observed. The difference was even more notable with the
response to the KMP-11 recombinant protein in which a
very low response was found during the acute phase. K1
(an amino-terminal peptide from this protein) also
induced significant reactivity in both groups of Colom-
bian chronic chagasic patients [29]. The data observed
here are consistent with that previously described in
humans and animal models where high levels of total IgG
specific response has been a hallmark of the sickness'
chronic stages [30,31].
The acute sera tested in the present study were from
patients involved in an outbreak of acute Chagas' disease
due to ingesting sugar cane juice where T. cruzi TcII lineage
was identified in nine patients [23]. It is possible that the
low reactivity observed in the acute phase group might
have been due to the early stage of infection (60 days)
since all patients presented high anti-T. cruzi IgM anti-
body titres (1:320) in immunofluorescence test. Another
explanation might be supported by the lineage of the T.
cruzi strain implicated. It has been recently described that
mice infection with T. cruzi TcI lineage, the main circulat-
ing lineage in Colombia [32], is correlated with higher
IgG responses compared with the T. cruzi TcII ones [33].
The highly conserved chaperone HSP-70 is a major cloned
sequence of pathogens which can induce cross-reactive
responses [34]. A fast acute chagasic patient IgG response
to TcHSP-70 may be explained by pre-existing specific
memory T cells, elicited by other HSP-70 pathogens.
Another non-exclusive explanation refers to the mitogenic
capability of HSP-70 for B cells which has been reported
for Leishmania infantum HSP-70 proteins in rodent mod-
els [35]. Similar to that reported by Requena et al., (1993)
using the whole HSP-70 parasite protein, sera from
healthy individuals in this study showed significant reac-
tivity against the T. cruzi truncated protein (TcHSP-70T).
This result was not surprising taking into account that the
truncated version's identity with the same region in the
human HSP-70 protein was a little bit higher (74%) than
when comparing the whole protein (70%). Moreover, the
truncated version lacks the C- terminal region in which
some parasite specific epitopes are located [34].
It is particularly worth noting that the response against the
complete T. rangeli HSP-70 protein was characterised by
Comparing normalised optical densities (OD) from sera eval- uated for both proteins Figure 3
Comparing normalised optical densities (OD) from 
from sera evaluated for TcHSP-70T and TrHSP-70 
recombinant proteins. The ELISA for the TcHSP-70T 
recombinant protein was performed with sera diluted 1/50 
and 1/100 for the TrHSP-70 antigen. Data was normalised by 
subtracting the mean OD of the healthy group for each pro-
tein and, when mean OD obtained was lower than 0, it was 
fixed as 0.BMC Infectious Diseases 2009, 9:186 http://www.biomedcentral.com/1471-2334/9/186
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higher reactivity in most chagasic patient sera, along with
the lack of it in healthy individuals.
This finding may have resulted from several GMPG motifs
being present at the T. rangeli HSP-70 protein's C-terminal
region. Besides, it has been demonstrated recently that
some  T. rangeli proteins can elicit a strong humoral
response in chagasic patients [36]. Collectively, these
results suggest that T. rangeli could be one of the patho-
gens which can boost antibody response to this antigen,
the HSP-70 protein seems to be involved in cross-reaction
between these trypanosomes and that the T. rangeli HSP-
70 protein could be explored for diagnosis strategies.
IgG subclasses were then measured against total crude
lysate and two recombinant proteins in all sera groups to
determine the relationship with disease stage. The data
showed that the specific antibodies in the acute patients
were from subclasses IgG3 and IgG4 against crude T. cruzi
antigen whereas IgG1 and IgG3 were the prevalent iso-
types in indeterminate and chronic chagasic patients.
These findings agreed with reported high prevalence for
IgG3 and IgG1 isotypes against epimastigotes in all clini-
cally severe stages of Argentinean and Brazilian chronic
chagasic individuals [37,38]. By contrast, Mexican cha-
gasic donors suffering cardiopathy had more IgG1 and
IgG2 and less IgG3 [39]. Moreover, anti-T. cruzi IgG2 asso-
IgG isotype profile against T. cruzi lysate Figure 4
IgG isotype profile against T. cruzi lysate. IgG1 (4A), IgG2 (4B), IgG3 (4C) and IgG4 (4D) isotype levels for patients in 
acute (AC), indeterminate (IND) and cardiac chronic phase (CCC) and healthy individuals (HD). Values are given as optical 
densities at 492 nm. The dotted line represents the cut-off values based on the mean of healthy individual values plus 3 stand-
ard deviations. Horizontal lines on each group represent mean and standard deviation values, the mean being the larger one. BMC Infectious Diseases 2009, 9:186 http://www.biomedcentral.com/1471-2334/9/186
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ciation with cardiac involvement or chronic cardiac dis-
ease severity has been reported in the Brazilian and
Mexican chagasic population, respectively [38,39]. These
apparently disagreeing results may have been due to dif-
ferences in the circulating parasite strain in each area.
Indeed, it has been shown recently that parasite genotype
can affect IgG subclass profile [33].
The specific prominent antibodies in all disease stages
against  T. cruzi KMP-11 and T. rangeli HSP-70 recom-
binant antigens were only from the IgG1 subclass. These
results were similar to those reported by Trujillo et al.,
(1999) using the Leishmania panamensis KMP-11 protein
[40].
Likewise, when an epimastigote acidic antigenic fraction
was used as antigen, IgG1 was the main antibody isotype
detected by ELISA in all Argentinean chronic patients [37].
On the contrary, the distribution of IgG subclasses against
epimastigote ribonucleoproteins and the cytoplasmic
(CRA) and flagellar (FRA) recombinant repetitive anti-
gens in chronic chagasic patients assessed by ELISA were
shared by IgG1 and IgG3 [41,42]. Since, IgG1 is a comple-
ment fixing antibody which also mediates cooperative
IgG isotypes profile against T. cruzi KMP-11 recombinant protein Figure 5
IgG isotypes profile against T. cruzi KMP-11 recombinant protein. IgG1 (5A), IgG2 (5B), IgG3 (5C) and IgG4 (5D) iso-
type levels for patients in acute (AC), indeterminate (IND) and cardiac chronic phase (CCC) and healthy individuals (HD). Val-
ues are given as optical densities at 492 nm. The dotted line represents the cut-off values based on the mean of healthy 
individual values plus 3 standard deviations. Horizontal lines on each group represent the mean and standard deviation values, 
the mean being the larger one.BMC Infectious Diseases 2009, 9:186 http://www.biomedcentral.com/1471-2334/9/186
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function with phagocytes through their Fc receptors [43],
then this specific antibody's role in controlling the infec-
tion or the disease progressing in severity needs to be
addressed.
Conclusion
The T. cruzi KMP-11 and the T. rangeli HSP-70 recom-
binant proteins may be explored together in Chagas' dis-
ease immunodiagnosis. Polarising the IgG response IgG1
subclass to T. cruzi KMP-11 and T. rangeli HSP-70 recom-
binant proteins could have important biological effects,
taking into account that this is a complement fixing anti-
body.
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